Small-Cap IPO Window Widens: Copper Foil and Metabolic Biotech Debut Wednesday, $492 Million Defense Roll-Up Next

by Maya Okafor · August 13, 2026

Deals & Listings Reporter, The SmallCap Signal

The new-issue market for smaller companies has stayed open into the second half of August, with two more offerings pricing late Tuesday, opening for trading Wednesday, and a defense-technology roll-up setting terms for a deal that would be one of the larger mid-cap listings of the quarter. The activity follows a week at the start of the month in which four clinical-stage biotechs came to market, and it leaves the small-cap issuance calendar busier than it has been at any point this summer.

Londian Wason New Energy Tech, a Shenzhen-based manufacturer, priced an upsized offering of about 4.3 million American depositary shares at $22 on the New York Stock Exchange under the ticker FOIL, the top of a marketed range of $20 to $22, for gross proceeds of approximately $94.3 million before the underwriters' option. The company said the pricing was announced August 11 and that trading was expected to begin August 12. Renaissance Capital noted the company sold about 0.7 million more ADSs than anticipated. Londian Wason produces electrolytic copper foil for lithium-ion batteries alongside electronic circuit foils and flexible copper-clad laminates, placing it in the industrials and metal fabrication category rather than the clean-energy developer bucket that has been harder to finance. The shares opened at $26 on Wednesday, roughly 18 percent above the offer price, and IPO data compiled by StockAnalysis showed them at $24.50 after the session, about 11 percent above the offer.

The second deal to price Tuesday night was Vogenx, which sold 6.25 million shares at $13 on the Nasdaq Capital Market under the ticker VOGX, the high end of its marketed range, for gross proceeds of approximately $81.3 million before a 45-day underwriters' option on a further 937,500 shares. Vogenx is a clinical-stage biopharmaceutical company focused on metabolic disease and is pre-revenue; its lead candidate, mizagliflozin, is an oral small molecule in development for post-bariatric hypoglycemia, gastroparesis and GIP-dependent Cushing's syndrome, and the company licensed worldwide rights to it excluding Japan, Korea and Taiwan from Kissei Pharmaceutical in 2021. StockAnalysis showed the stock at $13.00, level with the offer price, a flatter debut than the copper foil deal.

The week before was the busier one. Renaissance Capital, in its weekly recap covering August 3 through August 7, counted six IPOs, four of them biotechs. Braveheart Bio raised $383 million, was upsized and priced above its range at a $1.6 billion market capitalization, and gained 67 percent over the week, according to Renaissance; the company is developing oral cardiac myosin inhibitors for hypertrophic cardiomyopathy. Latigo Therapeutics raised $346 million at the top of its range at a $1.3 billion market capitalization and finished the week up 1 percent, while Attovia Therapeutics raised $289 million at the high end at a $767 million valuation and rose 19 percent. BlossomHill Therapeutics raised $150 million at the midpoint at a $503 million market capitalization and was flat.

The two non-biotech deals in that week fared less well at pricing. River City Bank raised $122 million on a downsized deal that priced below its range at a $637 million market capitalization, then added 4 percent, Renaissance reported. Ticketplus, a Latin American live-event ticketing marketplace and event software provider, raised $15 million at the bottom of its range at a $101 million market capitalization and fell 13 percent. Five blank-check companies also priced during the week, and two traditional IPOs plus eight SPACs filed.

Several of those names are now trading squarely in the small- and mid-cap range that defines this beat. StockAnalysis data compiled as of August 13, before Thursday's open, showed Braveheart Bio at $26.15 against an $18 offer price, Latigo at $19.38 against $18, and Attovia at $18.06 against $17. All three list on Nasdaq. Aftermarket premiums of this kind can compress once research coverage begins and lockup expirations approach, and none of these companies has an approved product.

The largest deal on the near-term calendar is Lyntris, which Renaissance Capital reported on August 10 has set terms for 24 million shares at $19 to $22 on the NYSE under the ticker LYNX, a $492 million offering valuing the company at about $2.4 billion at the midpoint. Pricing is expected during the week of August 17. Lyntris supplies connectivity systems to the US Department of Defense and allied militaries across sensor architecture, sensor hardware and data platforms used for maritime domain awareness, air and missile defense, and space communications. Renaissance said the company booked $451 million in revenue for the 12 months ended June 30, 2026, and was formed in 2026 through the combination of two previously separate businesses, Accelint and Vitesse, both formed by Trive Capital through a series of mergers. Evercore ISI, Citi, Guggenheim Securities, BofA Securities, Baird, Raymond James and William Blair are joint bookrunners.

One structural detail matters for anyone reading the Lyntris prospectus: Renaissance reported that 80 percent of the offering is secondary stock, meaning the bulk of the proceeds goes to existing holders rather than onto the company balance sheet. Sponsor-backed roll-ups assembled shortly before listing also carry integration risk that a longer operating history would help investors assess.

The two main trackers disagree sharply on how busy the year has been, largely because they count differently. StockAnalysis put the 2026 tally at 227 IPOs priced as of August 13, up 5.58 percent from the 215 recorded by the same point in 2025, a figure that sweeps in blank-check vehicles and very small offerings. Renaissance Capital's stats page counts 102 IPOs this year, down 24.4 percent from a year earlier, against $145.5 billion in total proceeds and 159 filings. Renaissance also reported its IPO Index up 18.8 percent year to date as of August 6, ahead of the S&P 500's 13.4 percent gain over the same stretch.

The wider backdrop is less settled than the calendar suggests. July producer prices, released Thursday morning, were unchanged on the month and up 4.7 percent from a year earlier, but the measure excluding foods, energy and trade services rose 0.4 percent on the month, a firmer core reading than June's 0.1 percent. Initial jobless claims came in at 209,000 for the week ended August 8, up 9,000. The Federal Reserve's July meeting minutes are due August 19, and the policy debate this cycle is over whether the next move is an increase rather than a reduction. Small-cap issuance windows have historically closed quickly when rate expectations move against risk assets, and a run of deals pricing at or above the top of their ranges is a measure of current demand, not a guarantee that the window stays open through September.